Condition: Healthy Subjects · Obesity · Type 2 Diabetes · Sponsor: OrsoBio, Inc
The phase 1 portion of the study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-6740 after single- and multiple-ascending doses in healthy subjects. The phase 1b portion of the study is designed to assess the safety, tolerability, and PK of TLC-6740 in subjects with obesity, with or without type 2 diabetes mellitus.
This description comes directly from the study's public registry record.
Ryan Huss, MD · 650-382-2225 · Clinicaltrials_Inquires@orsobio.com
Always discuss trial participation with your own doctor first.
| OrsoBio Auckland Research Site 1 | Auckland, New Zealand | Recruiting |
| OrsoBio Auckland Research Site 2 | Auckland, New Zealand | Recruiting |
| OrsoBio Auckland Research Site 3 | Auckland, New Zealand | Recruiting |
| OrsoBio Research Site | Christchurch, New Zealand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05822544